Apr 3, 2024, 06:05
Most viewed in the last 7 days from JAMA Oncology
JAMA Oncology shared a post on LinkedIn:
“Most viewed in the last 7 days from JAMA Oncology: Do patients with resectable NSCLC and tumor programmed cell death 1 ligand 1 levels less than 1% benefit from neoadjuvant chemo immunotherapy?”
Additional information.
Source: JAMA Oncology/LinkedIn
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Dec 21, 2024, 11:52
Dec 21, 2024, 11:30
Dec 21, 2024, 11:25
Dec 21, 2024, 11:18
Dec 21, 2024, 11:12
Dec 21, 2024, 11:06